MEDANTA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.3
| Stock Code | MEDANTA | Market Cap | 30,271 Cr. | Current Price | 1,127 ₹ | High / Low | 1,456 ₹ |
| Stock P/E | 57.6 | Book Value | 141 ₹ | Dividend Yield | 0.04 % | ROCE | 19.6 % |
| ROE | 15.2 % | Face Value | 2.00 ₹ | DMA 50 | 1,156 ₹ | DMA 200 | 1,218 ₹ |
| Chg in FII Hold | -0.87 % | Chg in DII Hold | 1.02 % | PAT Qtr | 128 Cr. | PAT Prev Qtr | 137 Cr. |
| RSI | 50.0 | MACD | -20.3 | Volume | 1,88,283 | Avg Vol 1Wk | 3,25,271 |
| Low price | 1,010 ₹ | High price | 1,456 ₹ | PEG Ratio | 1.82 | Debt to equity | 0.07 |
| 52w Index | 26.2 % | Qtr Profit Var | 22.6 % | EPS | 19.2 ₹ | Industry PE | 43.3 |
📊 Analysis: Medanta is trading at ₹1,127, below both its 50 DMA (₹1,156) and 200 DMA (₹1,218), indicating near-term weakness. RSI at 50.0 shows neutral momentum, while MACD at -20.3 suggests bearish undertone. Intraday volume (1.88 lakh) is below the 1-week average (3.25 lakh), limiting strong intraday moves. Valuation is stretched with a P/E of 57.6 compared to industry P/E of 43.3, suggesting overvaluation risk despite stable fundamentals.
💡 Optimal Buy Price: ₹1,115–1,125 (near support zone).
🎯 Profit-Taking Levels: ₹1,145–1,155 (short-term resistance near 50 DMA).
🛡️ Stop-Loss: ₹1,100 (below recent support).
⏱️ If Already Holding: Exit intraday if price fails to sustain above ₹1,115 or if MACD remains negative with weakening momentum. Consider booking profits near ₹1,145–1,155 if price action stalls and volume remains subdued.
✅ Positive
- Strong ROCE (19.6%) and ROE (15.2%) reflect decent capital efficiency.
- DII holdings increased by 1.02%, showing domestic institutional support.
- Quarterly PAT of ₹128 Cr. remains stable despite slight decline.
- Low debt-to-equity ratio (0.07) ensures financial stability.
⚠️ Limitation
- Trading below both 50 DMA and 200 DMA indicates weak technical setup.
- High P/E of 57.6 compared to industry average of 43.3 suggests overvaluation.
- Dividend yield of 0.04% offers negligible income appeal.
- Intraday volume weaker than average, reducing trading opportunities.
📉 Company Negative News
- Decline in FII holdings (-0.87%) signals reduced foreign investor confidence.
- PAT declined from ₹137 Cr. to ₹128 Cr., showing short-term earnings pressure.
📈 Company Positive News
- DII inflows (+1.02%) highlight domestic institutional confidence.
- Quarterly profit variation of 22.6% shows resilience in operations.
🏭 Industry
- Industry P/E at 43.3 is lower than Medanta’s 57.6, highlighting relative overvaluation.
- Healthcare sector demand remains strong with defensive characteristics.
🔎 Conclusion
Medanta shows limited intraday potential due to weak technicals, subdued volume, and overvaluation. While fundamentals remain stable and DII support is positive, bearish MACD and resistance near 50 DMA suggest caution. Suitable only for disciplined intraday traders with tight stop-loss and modest profit targets around ₹1,145–1,155.